Bisoprolol

Management of hypertension, alone or with other antihypertensives. This reference concerns standalone bisoprolol fumarate tablets; bisoprolol/hydrochlorothiazide combinations have another active ingredient and different dose/product considerations. No pediatric indication is established.

The 2022 AHA/ACC/HFSA guideline recommends bisoprolol as one of three evidence-based beta blockers for HFrEF with current/prior symptoms, reducing mortality/hospitalization. This is distinct from the selected U.S. hypertension indication and from starting treatment in overt unstable failure.

Usual hypertension start: 5 mg once daily; selected patients may start 2.5 mg. If inadequate, increase to 10 mg then 20 mg daily as needed. CrCl < 40 mL/min or hepatic impairment (hepatitis/cirrhosis): start 2.5 mg daily and titrate cautiously. No age-only reduction is required unless significant renal/hepatic dysfunction. Limited data suggest it is not dialyzable; routine dialysis replacement is unnecessary.

Guideline table: 1.25 mg once daily initially, target 10 mg daily as tolerated; GDMT reassessment/titration can occur every 1–2 weeks depending on symptoms, vital signs and labs. These are HFrEF guidance, not the 20 mg hypertension ceiling. Selected current U.S. tablets are 5/10 mg; the prescriber/pharmacist must establish an appropriate validated low-dose formulation, rather than assume a quarter-tablet or home-compounded dose is accurate.

Take the prescribed oral dose once daily; food does not affect absorption. In bronchospastic disease, generally avoid beta blockers; if necessary after other antihypertensive intolerance/failure, the label starts 2.5 mg with the lowest effective dose and available beta-2 bronchodilator. Do not interrupt independently. The label advises tapering over approximately one week under observation, including patients without evident coronary disease; withdrawal symptoms may require temporary reinstitution. Obtain missed-dose instructions and do not independently double.

Selected label: cardiogenic shock, overt cardiac failure, second- or third-degree AV block and marked sinus bradycardia. Do not silently add a pacemaker exception absent from this label or erase the overt-failure restriction because of chronic HFrEF guideline use. Bronchospastic disease is a strong avoidance/caution warning rather than a listed formal contraindication.

The selected current Micro Labs label has no boxed warning. Its abrupt-discontinuation warning remains clinically important; absence of a box does not permit unsupervised stopping.

Fatigue/asthenia, diarrhea, dizziness, headache, bradycardia and hypotension are reported; bronchospasm, worsening failure and severe allergy are important less-common risks. Trial-listed experiences do not establish drug causality for every event. Sporadic liver-test and other lab abnormalities are described. Overdose can cause severe bradycardia, hypotension, failure, bronchospasm and hypoglycemia: seek emergency/poison-center assessment; hospital supportive treatment may be required and dialysis is not expected to clear it effectively.

Medication reconciliation includes ophthalmic and other beta blockers.

No clinically relevant PK interaction was documented with studied thiazides/cimetidine, and no prothrombin-time effect was seen with stable warfarin. These observations do not remove additive antihypertensive effects, co-drug risks or the need for patient-specific review.

CrCl < 40 mL/min prolongs half-life about threefold; cirrhosis slows/varies elimination. Start 2.5 mg daily in labeled renal/hepatic impairment and titrate cautiously. Older adults need no age-only dose change, but renal function and pulse/BP may limit tolerance. No pediatric safety/effectiveness or dose is established.

No adequate controlled pregnancy studies; animal fetal toxicity at high exposures supports individualized benefit/risk assessment. Use in pregnancy only when potential benefit justifies fetal risk. Human milk excretion is unknown in the selected label; small amounts entered rat milk, so exercise caution and assess infant/maternal needs rather than claim established lactation safety.

Bisoprolol has no significant intrinsic sympathomimetic or membrane-stabilizing activity at therapeutic doses. Antihypertensive effects may involve lower cardiac output, reduced renin and reduced central sympathetic outflow. It slows sinus/AV-node function; at doses ≥ 20 mg it also blocks beta-2 receptors. BP/pulse effects can persist 24 hours.

Oral bioavailability about 80%; peak 2–4 hours, protein binding about 30%, half-life 9–12 hours and steady state within 5 days. Roughly half the dose appears unchanged in urine and the remainder mainly as inactive metabolites; renal and nonrenal clearance contribute. Food does not alter absorption. It is not metabolized by CYP2D6; do not infer absence of every other metabolic interaction.

Assess BP/pulse and symptoms before/after initiation and changes. Review dizziness/syncope, excessive bradycardia, chest pain, breathlessness, edema/weight change, peripheral circulation and bronchospasm. Monitor renal/hepatic context for dosing and glucose in at-risk patients. Consider ECG when conduction disease/symptoms or interacting medicines warrant; the label does not require routine serum drug levels.

Take consistently and do not stop/taper without a plan. Report slow-pulse symptoms, fainting, new swelling or breathing problems; urgent chest pain needs emergency evaluation. Know effects before driving/operating machinery. Tell clinicians about surgery, asthma, diabetes, thyroid disease and severe allergy. Keep the exact low-dose formulation plan clear when treated for HFrEF; do not substitute a combination tablet.

Micro Labs 5 mg tablet: pink, round, film-coated, deep score on one side and a bar-like imprint on the other; 30-tablet child-resistant bottle NDC 42571-470-30. Verify the actual written label and imprint, not color alone.

Selected standalone oral tablets: 5 and 10 mg; current FDA ANDA218303 lists both Prescription. This profile does not establish U.S. 1.25/2.5 mg tablet stock or any injectable/extended-release standalone product. Hydrochlorothiazide combination strengths/regimens are excluded.

Store 20–25°C, protect from moisture and dispense in tight light-resistant containers. Follow package expiry and child-resistant closure instructions. Dose splitting/compounding for a prescribed low dose requires pharmacist verification; do not infer accurate quartering from a single tablet score.